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Abstract
Motivation and negative symptom research has recently been hampered by a series of inconsistent 
findings, leading to calls for a greater consensus on the type of measures used across studies. To 
inform this issue, we conducted a meta-analysis that quantified the association between motivation 
measures (self-report, performance-based) and clinician-rated negative symptom measures as well 
as a series of moderator analyses to develop a greater understanding of the measurement factors 
impacting this relationship. Forty-seven eligible studies with people with schizophrenia-spectrum 
disorders were included. Using a random-effects meta-analytic model, a small but significant 
overall effect size emerged between motivation and clinician-rated negative symptoms (r = −.18). 
Several significant moderators were identified, including the generation of negative symptom 
measures such that there was a significantly stronger relationship between motivation and second-
generation (r = −.38) than first-generation negative symptom measures (r = −.17). Further, the type 
of performance-based measure used moderated the relationship, with effort discounting tasks most 
strongly related to negative symptoms (r = −.44). The domain of motivation assessed (intrinsic, 
extrinsic, amotivation) also moderated the relationship. These findings help to identify sources of 
inconsistencies observed in prior studies and point to both second-generation and effort 
discounting tasks as the most promising types of measures, particularly for those interested in 
validating motivation measures or assessing the effectiveness of motivation treatments. Although 
additional research is needed, our results suggest that using these measures may help to reduce 
inconsistencies across studies and move the field forward.
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1. Introduction
Motivation—an internal state that directs and sustains goal-directed behavior (Kleinginna 
and Kleinginna, 1981)—is often impaired among those with schizophrenia (Cooper et al., 
2015; Fervaha, Foussias, et al., 2015). These reductions contribute to reduced quality of life, 
social relationships, and occupational attainment (Fervaha, Foussias, et al., 2014; Foussias et 
al., 2011; Thomas et al., 2017; Vancampfort et al., 2013). While motivation deficits have 
recently been categorized as a core subdomain of negative symptoms, there is still debate 
about the role that motivation deficits play in negative symptoms. For example, the National 
Institute of Mental Health’s Measurement and Treatment Research to Improve Cognition in 
Schizophrenia (NIMH-MATRICS; Kirkpatrick et al., 2006) Consensus Development 
Conference on Negative Symptoms indicated that amotivation was one of the five principal 
negative symptom domains alongside anhedonia, asociality, restricted affect, and alogia. 
However, some researchers posit that amotivation is actually the primary overarching 
negative symptom (Foussias and Remington, 2008) or one of two overarching negative 
symptom factors (Sarkar et al., 2015). Further, the degree to which these conceptualizations 
align with widely used negative symptom measures varies, with several commonly used 
negative symptom measures differing in the extent to which motivation deficits are assessed 
(Foussias and Remington, 2008). These differences have contributed to the inconsistent 
findings plaguing much of motivation research (Hartmann-Riemer et al., 2018; Kremen et 
al., 2016), making interpretation of findings across studies difficult and hindering the field 
from moving forward. For example, depending on the negative symptom measure used, 
associations with similar motivation measures have ranged from nonsignificant to large 
(Hartmann et al., 2015; Tobe et al., 2016; Wolf et al., 2014). Given the functional 
significance of motivation and the common use of negative symptom measures as a main 
outcome in motivation treatment trials (Green et al., 2015; Kirkpatrick et al., 2006), 
ascertaining which negative symptom measures are best assessing reduced motivation is 
critical. Indeed, if negative symptom measures do not adequately assess motivation deficits, 
then using them to assess the efficacy of interventions targeting motivation may lead to an 
inaccurate evaluation of these interventions. Thus, in an effort to understand the 
inconsistencies and to help researchers identify the best negative symptom measures for 
clinical trials targeting motivation, this study aimed to synthesize the associations between 
motivation and negative symptom measures.
Clinician-rated measures have long been the gold-standard for assessing negative symptoms. 
Although developed over thirty years ago, two commonly-used clinician-rated measures are 
the Scale for the Assessment of Negative Symptoms (SANS; Andreasen, 1982) and the 
Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987). However, these older 
measures (referred to here as first-generation) may be problematic for assessing newer 
treatments and measures as the conceptualization of negative symptoms in schizophrenia 
research has changed. Indeed, first-generation measures often include items such as attention 
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or abstract thinking that are now considered a separate domain related to cognition (Harvey 
et al., 2006) or contain individual items that conflate seperable symptoms or processes 
(Horan et al., 2006). Further, first-generation scales can emphasize behavioral indicators at 
the expense of understanding internal experiences linked to negative symptoms (Blanchard 
et al., 2011). However, internal experiences are particularly important for motivation, given 
that one’s drive or interest in a particular activity even in the absence of behavior indicates 
that motivation at some level is present.
Partially as a result of these limitations, the NIMH-MATRICS negative symptoms consensus 
statement (Kirkpatrick et al., 2006) recommended creating new negative symptom measures 
(“second-generation”) to address these limitations. This resulted in the development of the 
Clinical Assessment Interview for Negative Symptoms (CAINS; Horan et al., 2011; Kring et 
al., 2013) and the Brief Negative Symptom Scale (BNSS; Kirkpatrick et al., 2010; Strauss et 
al., 2012). Although these second-generation scales have demonstrated promising 
psychometric findings, including strong convergent validity with first-generation negative 
symptom assessments (Kring et al., 2013), limited empirical evidence suggests that second-
generation measures are indeed better capturing individual negative symptom domains such 
as motivation deficits than first-generation scales. Further, first-generation scales are still 
widely used. If we are to create greater consensus in measurement and reduce 
inconsistencies across studies examining motivation so that we can better help people 
struggling with these deficits, we need more research focused on identifying whether 
second-generation scales are truly better at assessing different symptom domains than first-
generation measures.
Consistent with the range of conceptual approaches for negative symptoms, schizophrenia 
researchers have also approached measuring and conceptualizing motivation in several ways. 
Many schizophrenia researchers have looked to arguably the most prominent theory of 
motivation, Self-Determination Theory (SDT; Deci and Ryan, 1985; Ryan and Deci, 2000, 
2017) to elucidate the multidimensional nature of motivation (Choi et al., 2010; Medalia and 
Brekke, 2010; Silverstein, 2010). Briefly, SDT explicates that there are different types of 
motivation that can be distinguished by the sources or reasons for the behavior. Specifically, 
SDT posits that motivation has three domains: 1) intrinsic motivation—behaviors or 
activities that are performed because they are inherently interesting and the primary 
“reward” is the associated feelings of enjoyment or satisfaction, 2) extrinsic motivation—
behaviors that are completed in order to attain a separable outcome from the activity such as 
an external financial reward, social praise, evasion of punishment, or an esteemed outcome, 
and 3) amotivation—lack of behaviors or intentions to engage in or complete an activity 
(Ryan and Deci, 2000, 2017; Deci, Olafsen, et al., 2017). Further, these motivation domains 
can also be impacted by one’s environment and fulfillment of the three basic psychological 
needs of competence, relatedness or belongingness, and autonomy or self-regulation (See 
Deci and Ryan, 2000; Ryan and Deci, 2017 for more information). Given SDT’s prominent 
role in schizophrenia motivation research, several frequently used motivation self-report 
measures are SDT-derived measures, including the Intrinsic Motivation Inventory for 
Schizophrenia Research (IMI-SR; Choi et al., 2014), which assesses intrinsic motivation for 
a specific task. Other commonly used self-report motivation measures also align with the 
SDT-derived domains, including the self-report Apathy Scale (AES-S; Marin et al., 1991) or 
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Self-Evaluation of Negative Symptoms (SNS; Dollfus et al., 2015), which both assess 
amotivation.
More objective, performance-based motivation measures have also recently been developed 
to measure how willing participants are to work for external rewards. These measures, 
generally referred to as effort-based decision-making tasks, overcome some limitations 
associated with self-report and clinician-rated measures (e.g., reliance on ability to recall 
information, extensive training needed to reliably administer/score measures) and can 
elucidate compromised subprocesses or mechanisms that might underlie motivation deficits 
(Green et al., 2015). Indeed, many of the performance-based measures have been translated 
from animal paradigms that have been linked to specific neural mechanisms related to 
reduced motivation (e.g., Anterior cingulate cortex dysfunction; ventral striatal dopamine 
depletion (Fervaha, Foussias, et al., 2013)), which can help to pinpoint whether these regions 
are also implicated in motivation deficits in humans with schizophrenia. Despite these 
promising benefits, this avenue of research has been hampered by inconsistent findings in 
the magnitude and even direction of the relationship between performance-based motivation 
measures and negative symptoms (McCarthy et al., 2016; Reddy et al., in press), leading to 
questions about the utility and validity of these measures.
A main source of the inconsistencies observed in prior studies likely stems from the type of 
performance-based or clinician-rated negative symptom measures used. Indeed, there are 
three broad types of performance-based motivation measures currently used. The first type, 
forced-choice non-adaptive reward tasks, are the most-widely used and involve tasks where 
participants complete a number of forced-choice trials where they select to complete either a 
low effort task that provides low monetary reward (usually fixed at for example $1.00) or a 
task involving relatively greater effort that offers larger rewards (usually variable, e.g., 
ranges between $1.24 - $4.30). Importantly, the reward values are not modified over time 
based on participant responses, and the most commonly used indicator of motivation is the 
number of hard choices chosen across trials. In contrast, effort discounting tasks use reward 
manipulation to identify the indifference point, which is the amount of reward when a person 
becomes indifferent to completing the low effort and high effort task options. The third type 
of task, progressive ratio tasks, generally involve single choice trials where the level of effort 
needed to attain a reward increases over time and motivation is indicated by the greatest 
effort amount a person is willing to expend (breakpoint score). Notably, across all three 
types of tasks, effort can be physical (e.g., button presses, handgripping) or cognitive (e.g., 
identifying whether numbers are greater than or equal to a specified number). Further, extant 
studies examining the association between these tasks and clinician-rated negative symptoms 
have yielded mixed results. For example, some studies using forced-choice non-adaptive 
reward tasks have found small but significant inverse associations (Barch et al., 2014; Horan 
et al., 2015), while others have failed to find significant associations (Fervaha, Duncan, et 
al., 2015; Moran et al., 2017), found a trend level association (Treadway et al., 2015), or 
even an unexpected positive association with clinician-rated negative symptoms (McCarthy 
et al., 2016). On the other hand, compared to forced-choice non-adaptive reward tasks, some 
studies examining the magnitude of the relationship between both effort discounting and 
progressive ratio tasks and clinician-rated negative symptoms have found relatively stronger 
associations with negative symptoms (i.e., medium to large (Culbreth et al., 2016; Strauss et 
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al., 2016; Wolf et al., 2014); but also see Bismark et al., 2018 & Docx et al., 2015). A 
synthesis of these prior studies, which were often based on small samples, can help to clarify 
the degree to which each type of task is capturing a process related to negative symptoms 
and can help to realign our efforts towards the most promising and beneficial assessment 
approaches. Further, identifying which type of performance-based measure is most strongly 
aligned to negative symptoms can help to more precisely elucidate behavioral and neural 
mechanisms underlying negative symptoms, which can help to inform novel treatment 
development.
The present study aimed to inform conceptual and measurement issues surrounding 
motivation and negative symptoms in people with schizophrenia by first conducting a 
metaanalysis that quantified the relationship among motivation measures and clinician-rated 
negative symptom measures. Although prior literature examining this association has been 
mixed (Barch et al., 2014; Fervaha, Duncan, et al., 2015), based on the conceptual link, we 
hypothesized that that there would be a significant, small overall effect size between these 
measures. To develop a more precise understanding of the different measurement and 
conceptualization factors as well as participant characteristics that may affect this 
relationship, we then examined a series of potential moderators:
1. Type of motivation measure (i.e., self-report versus performance-based). Given 
both self-report motivation and clinician-rated negative symptom assessments 
incorporate self-report participant information, we hypothesized that self-report 
motivation measures would have a stronger relationship with negative symptoms 
than performance-based measures.
2. Negative symptom measure type (i.e., first-generation versus second-generation). 
Because second-generation measures were developed to more comprehensively 
assess negative symptom domains, we hypothesized that motivation would 
demonstrate a stronger relationship with second-generation rather than first-
generation negative symptom measures.
3. Motivation domain (i.e., intrinsic, extrinsic, or amotivation). We hypothesized 
that the relationship would be strongest between amotivation and negative 
symptoms given their stronger conceptual overlap.
4. Participant characteristics that might impact the magnitude of the relationship, 
including factors previously associated with motivation such as illness length 
(Luther et al., 2015) and antipsychotic medication dose (Kirsch et al., 2007; 
Luther et al., 2016). These moderator analyses were exploratory.
2. Methods
2.1. Literature Search
Guidelines from the evidence-based Preferred Reporting Items for Systematic Reviews and 
Meta-Analysis (PRISMA; Moher et al., 2009) were followed. Once we discussed our search 
strategy with a science-focused librarian, we identified eligible studies in three steps. First, 
keywords including derivatives of motivation, schizophrenia, and a comprehensive 
combination of measurement terms (e.g. self-report, performance-based) were searched in 
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Embase, Medline, PsychINFO, PsychARTICLES, Pubmed, and Web of Science Core 
Collection in September 2017. We selected relevant filters (i.e., English, human-based 
studies) when possible. Conference presentations and dissertations were included to reduce 
publication bias (Borenstein et al., 2009; Lipsey and Wilson, 2001). We next examined the 
references of reviews focused on motivation in schizophrenia (i.e., Green and Horan, 2015; 
Green et al., 2015; Kremen et al., 2016; Markou et al., 2013; Medalia and Brekke, 2010; 
Reddy, Horan & Green, 2015; Strauss et al., 2014). Lastly, because studies were required to 
use either a self-report or performance-based assessment of motivation, forward searches of 
the corresponding seminal measure articles were conducted.
2.2. Study Eligibility Criteria
Eligible studies were those that 1) were obtainable in English; 2) used an empirical self-
report and/or performance-based motivation assessment and a global (i.e., measured multiple 
domains) clinician-rated negative symptom measure. We aimed to look at global negative 
symptoms and not negative symptom factors (e.g., experiential and expressive negative 
symptoms (Llerena et al., 2018)) based on the conceptual issues mentioned above (e.g., 
some individual negative symptom items conflate different symptoms) and differing 
empirical evidence supporting the presence of and included negative symptom domains 
(e.g., anhedonia) in experiential and expressive negative symptom factors across negative 
symptom measures, particularly between first-generation and second-generation negative 
symptom measures (Ahmed et al., in press; Blanchard and Cohen, 2006; Liemburg et al., 
2013). For the motivation assessments, we also did not include clinician-rated motivation 
scales for analytic purposes (e.g., in order to avoid shared method variance that would likely 
conflate the strength of the associations found) and feasibility reasons (e.g., clinician-rated 
motivation is largely assessed via subscales of negative symptom measures); 3) had a 
motivation measure that aligned with intrinsic motivation, extrinsic motivation, or 
amotivation; choosing measures that align with these domains helps to decrease the 
difficulties operationalizing motivation, lessens construct validity concerns, and is consistent 
with the widely used and theoretically driven SDT-based conceptualizations of motivation in 
schizophrenia research; 4) the self-report and clinician-rated assessments used aligned with 
reviews of motivation and negative symptoms by Kremen et al. (2016) and Lincoln et al. 
(2017), and the performance-based tasks used were consistent with those described in the 
review from Markou et al. (2013). We chose these reviews because they detail the most 
widely used and validated motivation and negative symptom measures, which is important 
for reducing content validity issues; 5) used these measures with a schizophrenia-spectrum 
sample; and 6) contained a univariate association among motivation and overall negative 
symptoms; if these variables were assessed with eligible measures, but the univariate 
association was not reported, we emailed the study authors. In treatment or experimental 
studies, we only included baseline relationships. Studies were omitted when samples 
overlapped with another included study or univariate associations were unable to be 
collected after emailing study authors.
2.3. Coding
Studies were coded following published strategies (Card, 2012; Lipsey and Wilson (2001). 
Sample characteristics included age, gender, illness length, chlorpromazine equivalent doses, 
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and diagnoses. We coded measure name and score used, measurement type, motivation 
domain assessed (based on Kremen et al. (2016), Lincoln et al. (2017), and Markou et al. 
(2013)) and generation of negative symptom measure (i.e., second-generation measures were 
those created based on the NIMH-MATRICS negative symptoms consensus statement 
(Kirkpatrick et al., 2006)).
2.3.1. Effect Size Coding—We extracted effect size information (e.g., correlation 
coefficient) that represented the univariate relationship between motivation and negative 
symptoms for each study. Effect sizes were first changed into Pearson’s correlations and 
coded so higher motivation measure values represented greater motivation, and higher 
negative symptom levels represented more negative symptoms. Correlations were then 
transformed using Fisher’s Z-transformation and weighted based on sample size. Following 
the recommendation of Card (2012) and Lipsey and Wilson (2001), if a study contained 
more than one effect size, we averaged the effect sizes to reduce bias and maintain statistical 
independence (Card, 2012). Meta-analytic calculations were conducted in Comprehensive 
Meta-Analysis, V. 3 (CMA; Borenstein et al., 2015).
2.4. Analyses
To quantify the overall association between motivation and negative symptoms, we 
calculated the mean overall effect size based on a random-effects model. Cohen (1992)’s 
recommendations for correlations (.10 = small, .30 = medium, .50 = large) were used to 
interpret the effect size magnitude.
For moderation analyses, we used the Q-statistic to identify whether significant (p < .05) 
heterogeneity was present (Card, 2012), and the I2 index was used to identify the percentage 
of variation resulting from between-study variability (Higgins and Thompson, 2002; Huedo-
Medina et al., 2006). Moderation analyses were completed if the Q-statistic was significant 
and the I2 index ≥ 25%, as this I2 value suggests greater variability than expected by chance 
(Huedo-Medina et al., 2006). We used an Analysis of Variance analog to test categorical 
moderators and meta-regressions to test continuous moderators. Continuous moderators 
were significant when the significance of the beta weight was p <.05; categorical moderators 
were significant when (Qbetween was significant (p <.05).
To determine that no individual study disproportionately impacted the overall effect size, we 
utilized a one-study removed sensitivity analysis (Borenstein et al., 2009). Studies that 
looked like outliers on forest plots as well as greatly changed the effect size if excluded were 
considered for removal. We examined publication bias by examining the funnel plot and 
conducting Egger’s regression approach (Egger et al., 1997) to assess for asymmetry. Bias is 
likely present when the funnel plot has an asymmetrical distribution (Card, 2012) and the 
Egger’s test intercept is significant (p <.05) (Egger et al., 1997).
3. Results
3.1. Study Characteristics
Our search yielded 47 eligible studies (Figure 1 contains the Study Retrieval Flow Diagram). 
Included study summary characteristics are reported in Table 1; study characteristics, 
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measure information, and effect sizes for each study are reported in Table 1 in the online 
supplemental material. Across all studies, 2,908 people diagnosed with a schizophrenia-
spectrum disorder were included. Thirty-three studies included a self-report motivation 
measure (most commonly a version of the Intrinsic Motivation Inventory (IMI; Ryan, 
1982)), 12 included a performance-based motivation measure (predominantly the Effort 
Expenditure for Rewards Task (Treadway et al., 2009)), and two included both motivation 
measurement types. The majority of studies used self-report measures that assessed 
amotivation (k= 24); fewer studies used self-report measures of intrinsic (k= 14) and 
extrinsic motivation (k = 3). For negative symptoms, thirty-four studies used a first-
generation negative symptom measure (most commonly the PANSS), three used a second-
generation measure, and ten used both generations of negative symptom measures. Table 1 
of the online supplemental material details included measures.
3.2. Sensitivity Analysis
The one-study removed forest plot suggested there was variation among effect sizes; 
however, McCarthy et al. (2016)’s study appeared to be overly impacting the overall effect 
size based on the effect size point estimates. Since McCarthy et al. (2016) also had divergent 
demographics (e.g., was older), this study was excluded from the remaining analyses. All 
other studies were retained.
3.3. Main Analyses
3.3.1. Overall motivation—negative symptoms meta-analysis—The remaining 
46 studies were used in the meta-analysis evaluating the overall association between 
motivation and negative symptoms (see Figure 2). In accord with our hypothesis, we 
observed a small, negative, significant effect size (r = −.18, p <.001, 95% Cl [−.24, −. 12]), 
such that greater motivation was associated with lower negative symptoms. Individual study 
correlations were between r = −.55 to r= .15. In regards to heterogeneity, the Q- statistic was 
significant (Q = 104.13, P <001), and the I2 index was 56.78%; thus, moderator analyses 
were conducted.
3.4. Moderator Analyses
3.4.1. Motivation measurement type—Contrary to hypotheses, categorical moderator 
analyses indicated that the motivation measurement type did not moderate the relationship 
between motivation and negative symptom measures (Qbetween = 1.39, p = .24; see Table 
2). Both measurement types demonstrated significant but small inverse relationships with 
negative symptoms (self-report: r = −.19, p < .001; performance-based: r = −.14, p= .003).
To further identify whether a specific performance-based measure might be best capturing 
negative symptoms, we explored whether the type of performance-based measure used 
moderated the relationship. Significant moderation was observed (Qbetween = 6.53, p = .
04); effort discounting tasks demonstrated the strongest—and only significant—relationship 
with negative symptoms (r = −44, p = .001), followed by progressive ratio (r = −.12, p = .23) 
and the forced-choice non-adaptive reward tasks (r = −.09, p = .09). However, these analyses 
were based on few studies and were likely underpowered.
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3.4.2. Negative symptom measurement—As hypothesized, the generation of 
negative symptom measure moderated the motivation and negative symptoms association 
(Qbetween = 23,35, p < .001), such that there was a significantly stronger inverse 
relationship between motivation measures and second-generation (r = −.38, p < .001) rather 
than first-generation negative symptom measures (r = −.17, p < .001). In exploratory 
analyses, we separately examined whether motivation measurement subtypes (self-report, 
performance-based) were also more strongly associated with second-generation negative 
symptom assessments. Similar to our overall analyses, generation of negative symptom 
measure significantly moderated the self-report motivation and negative symptoms 
association (Qbetween = 25.38, p < .001). Self-report motivation measures demonstrated a 
significantly stronger relationship with second-generation (r = −.45, p < .001) rather than 
first-generation (r = −.18, p < .001) negative symptom measures. For performance-based 
motivation measures, we also observed that the generation of negative symptom measure 
was a significant moderator (Qbetween = 4.02, p = .045); performance-based motivation 
measures had a significantly stronger relationship with second-generation (r = −.26, p < .
001) as opposed to first-generation (r = −.10, p = .04) negative symptom measures.
We also explored whether the specific negative symptom measure affected the magnitude of 
the relationship with motivation. Significant moderation was observed (Qbetween = 24.54, p 
< .001), with the BNSS (r = −.39, p < .001) and CAINS (r = −.36, p < .001) demonstrating 
the strongest associations with overall motivation. Of the first-generation measures, the 
negative symptom factors from the PANSS (r = −.21, p < .001) and Brief Psychiatric Rating 
Scale (Overall and Gorham, 1962) (r = −.22, p < .001) demonstrated relatively stronger 
associations than the SANS (r = −.12, p < .001) and Negative Symptom Assessment (NSA; 
Alphs et al., 1989) (r = −.11, p = .28). However, given that the NSA was only used in one 
study, these results should be interpreted cautiously.
3.4.3. Motivation domain—The motivation domain assessed also significantly 
moderated the association between self-report motivation and negative symptoms (Qbetween 
= 6.86, p = .03). As hypothesized, the strongest relationship was between self-report 
amotivation and negative symptoms (r = −.22, p < .001); of note, this relationship suggests 
that higher amotivation is associated with higher negative symptoms (correlations were all 
coded such that higher scores = greater motivation). The self-report intrinsic motivation and 
negative symptoms association was weaker but still significant (r = −.12 p = .005), whereas 
the association with self-report extrinsic motivation was even weaker and non-significant (r 
= −.06, p = .47).
3.4.4. Participant Characteristics—Five characteristics were examined as moderators 
of the overall association between motivation and negative symptoms: average age, illness 
length, and chlorpromazine equivalent doses and percent female and percent of the sample 
with a schizophrenia diagnosis; none were significant moderators.
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3.5. Publication Bias
The funnel plot of the effect sizes for the overall motivation and negative symptoms 
association was relatively symmetrical and triangular, and Egger’s test was not significant (p 
= .89), indicating that publication bias was likely not present.
4. Discussion
Motivation and negative symptom research has recently been hampered by a series of 
inconsistent findings, leading to calls for a greater consensus on the type of negative 
symptom and motivation measures used (Hartmann-Riemer et al., 2018). To inform this 
issue, we first conducted a meta-analysis that quantified the relationship between motivation 
measures (self-report, performance-based) and clinician-rated negative symptom measures 
to develop a greater understanding of the consistency of the relationship and the role 
motivation deficits play in negative symptoms. Consistent with our hypothesis, we observed 
a small but significant negative association between overall motivation and clinician-rated 
negative symptoms (r = −.18), with motivation explaining 3.24% of the variance in clinician-
rated negative symptom measures. These results build on prior findings by including a 
substantial amount of unpublished data, with only 11 of the 47 (23.4%) studies previously 
publishing these univariate associations between motivation and negative symptom 
measures. In addition, this study overcomes the shortcomings of many prior studies that 
included small samples by pooling together data from 2,908 people with schizophrenia-
spectrum disorders. Moreover, we were able to systematically assess potential sources of 
variability in the relationship between motivation and negative symptom measures through 
moderator analyses, and our findings point to generation of negative symptom measure, type 
of performance-based measure, and domain of self-report motivation measure used as 
primary candidates that might explain some of the inconsistencies observed in the literature.
Notably, the amount of variance explained by motivation measures in negative symptoms 
was small (i.e., 3.24%). Indeed, the NIMH-MATRICS negative symptoms consensus 
statement (Kirkpatrick et al., 2006) and recent empirical findings indicate that motivation is 
one of five key negative symptoms (Ahmed et al., in press). Further, others have posited that 
amotivation is actually the primary overarching negative symptom (Foussias & Remington, 
2008) or one of two key negative symptom factors (Sakar et al., 2015). Although these 
conceptualizations differ in the extent that motivation deficits play in negative symptoms, 
they all indicate that motivation deficits should explain more than 3.24% of the variance in 
negative symptoms. If measures do not give enough weight to negative symptoms domains 
that are critical to improved functioning and quality of life, such as motivation deficits, using 
these tools to evaluate the effectiveness of negative symptom interventions may fail to 
capture clinically significant or meaningful change. Indeed, consistent with 
recommendations for clinical trials targeting negative symptoms (Marder et al., 2013), 
global or total negative symptom scores are often used as endpoints in clinical trials; 
however, our results suggest that using a clinician-rated negative symptom total score alone 
may lead to an underrepresentation of improvements on motivation deficits. Thus, although 
more work is needed to clarify the role of reduced motivation in negative symptom 
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conceptualizations, these findings suggest that negative symptom measures by themselves 
may not adequately capture motivation deficits.
Regarding the generation of negative symptom measure, there was a significantly stronger 
overlap between overall motivation and second-generation (medium effect) than first-
generation (small effect) negative symptom measures. Further, both self-report and 
performance-based measures of motivation were more strongly related to second-generation 
as opposed to first-generation measures. Similarly, our exploratory analyses with specific 
negative symptom measures showed that the two second-generation negative symptom 
assessments, the BNSS and CAINS, demonstrated the strongest relationships with 
motivation measures. Although prior theoretical articles have suggested that second-
generation negative symptom measures are better at capturing negative symptom domains 
such as reduced motivation (Blanchard et al., 2011), our findings provide much needed 
empirical evidence for this supposition. Further, they suggest, that we should not expect 
large correlations between motivation measures and the first-generation negative symptom 
measures included in these analyses. Indeed, these findings are consistent with one of the 
goals of the second-generation negative symptom measures, which is to assess motivation 
deficits in terms of both intentions and behaviors (i.e., desire and actual engagement) in 
order to overcome the concern that first-generation measures primarily focus on behaviors. 
Capturing internal processes related to motivation may help to not only yield a more 
comprehensive picture of motivation deficits, especially when environmental restrictions 
may limit behaviors, but also help to improve the consistency of the relationship between 
motivation and negative symptom measures. Thus, these findings suggest that it may be 
time, particularly for those interested in validating motivation measures or assessing the 
efficacy of motivation treatments, for a more comprehensive shift towards using second-
generation measures as a means to reduce inconsistencies resulting from measurement issues 
across studies.
Exploratory analyses found that the type of performance-based motivation measure 
significantly moderated the motivation and negative symptoms association. Specifically, the 
strongest and only significant relationship was with effort discounting tasks, followed in 
magnitude by the progressive ratio tasks, with the forced-choice non-adaptive reward task 
showing the weakest relationship with negative symptoms. Although our results should be 
interpreted cautiously given that some tasks were used in few studies, these findings suggest 
that effort discounting tasks may be the most promising tasks for elucidating key behavioral 
or neural mechanisms related to negative symptoms in people with schizophrenia. 
Alternatively, the forced-choice non-adaptive reward tasks demonstrated little overlap with 
negative symptoms, suggesting that these measures, or at least the score commonly used to 
represent motivation (i.e., % hardest tasks chosen), may not be a sensitive enough measure 
for negative symptomology or that other factors such as defeatist performance beliefs may 
more strongly influence the relationship between this type of task and negative symptoms 
(Reddy et al., in press). While additional research assessing the relationships between these 
tasks and negative symptoms is needed, our results provide preliminary evidence indicating 
that our resources may be best focused on effort discounting tasks to further refine and 
develop our conceptualization of motivation and negative symptoms in people with 
schizophrenia.
Luther et al. Page 11
Schizophr Res. Author manuscript; available in PMC 2020 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
An additional source of variability in the motivation and negative symptoms association was 
the motivation domain assessed among self-report measures. Consistent with our hypothesis, 
we observed the strongest relationship, albeit still small in magnitude, between amotivation 
and negative symptoms. Intrinsic motivation and negative symptoms also demonstrated a 
small, significant relationship, while the extrinsic motivation and negative symptoms 
association was negligible and non-significant. These findings align with amotivation being 
a key negative symptom domain according to the NIMH-MATRICS negative symptom 
consensus statement (Kirkpatrick et al., 2006) as well as the notion that targeting intrinsic 
motivation with psychosocial treatments may lead to negative symptom reductions (Kremen 
et al., 2016). However, our observed associations between both intrinsic and extrinsic 
motivation and negative symptoms indicate that there may be less overlap between these 
domains—when self-reported—and negative symptoms than previously thought. Although 
these constructs are often categorized under the broader umbrella of motivation deficits or 
negative symptoms, our findings indicate we should not always expect to observe large 
correlations between the motivation domains of intrinsic and extrinsic motivation and 
negative symptoms despite their theoretical overlap. Further, in addition to negative 
symptom scales, these results support the use of multi-domain assessments of motivation to 
provide a more complete assessment, particularly in validation and treatment studies 
targeting these motivation domains.
There were also several factors that did not influence the strength of the relationship 
between motivation and negative symptoms. First, none of the participant characteristics 
examined moderated the relationship, suggesting that the measurement factors noted above 
may be greater contributors to the inconsistent relationships across studies. There was also 
no significant difference in the magnitude of the relationship between type of motivation 
measure (self-report, performance-based) and negative symptoms—both motivation 
measurement types evidenced small but significant relationships with negative symptoms. 
Taken together with studies finding limited overlap among motivation self-report and 
performance-based assessments (Luther et al., 2018), this may indicate that these forms of 
motivation assessments are capturing divergent—although similar overall amounts—of 
underlying processes related to negative symptoms. Further, the smaller than expected 
relationship between self-reported motivation and negative symptom measures may also 
suggest that intentions or perceptions of behavior captured by self-report measures do not 
always lead to or map on to behaviors, particularly in the time-frames that are assessed by 
clinician-rated negative symptom measures.
As with all meta-analyses, this study is impacted by the limitations of the included studies, 
including the use of convenience sampling. One potential limitation specific to this study 
was that not all measures purported to measure motivation were included; however, we 
chose to narrow our focus, guided by SDT and prior literature, to increase construct validity. 
Similarly, for the analytic and feasibility methods previously mentioned, we did not examine 
the association between clinician-rated motivation and negative symptoms. However, this 
likely resulted in a less biased (i.e., reduced shared method influence) estimate of the 
motivation and negative symptoms association. Relatedly, not all existing negative symptom 
measures were used in the eligible studies; thus, these results can only be applied to the 
negative symptom measures that were included in our analyses. Some of our analyses with 
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performance-based motivation measures or individual negative symptom scales (i.e., NSA) 
were also based on few studies and were likely underpowered; these results should be 
interpreted with caution. Indeed, given that the NSA was only used in one eligible study, 
additional research clarifying the association between motivation measures and the NSA is 
needed. Further, although the majority of the studies included used similar scoring methods 
for measures like the PANSS and SANS, differing scoring methods or negative symptom 
factors were used across studies or exist in the literature; additional work is needed to create 
a greater consensus on the scoring methods that best capture motivation deficits or negative 
symptoms. Further, partly due to motivation’s functional significance, we focused on this 
negative symptom domain, but additional work is needed to evaluate associations between 
measures of the remaining negative symptom domains (e.g., anhedonia, blunted affect) and 
first-generation and second-generation negative symptom measures. Similarly, future 
research could clarify the associations between individual negative symptom domains and 
negative symptom factors (e.g., experiential and expressive negative symptoms), particularly 
by using second-generation negative symptom scales that may have more distinguishable 
factors than some of the first-generation negative symptom scales. Finally, we were limited 
by the state of the motivation and negative symptom schizophrenia research, and as these 
results highlight, there is still much to improve and understand about measuring and 
ultimately treating these domains.
Despite these limitations, our findings have important implications for motivation and 
negative symptom measurement, research, and treatment. In order to truly help those with 
motivation deficits, we need greater consistency in the types of motivation and negative 
symptom measures used in this line of research. Our findings offer insights into some 
measurement factors that might reconcile some of the inconsistency and point to the most 
promising measures to assess these symptoms. First, our results suggest that second-
generation negative symptom assessments (i.e., BNSS, CAINS) are more strongly aligned 
with self-report and performance-based assessments of motivation than first-generation 
measures. Thus, for those interested in validating motivation measures or assessing the 
effectiveness of motivation treatments, second-generation measures may best capture the 
motivational subdomain of negative symptoms. From the motivation side of assessment, our 
results point towards effort discounting tasks as explaining the largest quantity of variance in 
negative symptoms. These results also provide preliminary evidence indicating that of the 
three types of performance-based assessments, effort discounting tasks may be the most 
promising for elucidating subprocesses and neural regions linked to negative symptomology. 
Finally, despite their theoretical similarities, our results suggest that motivational 
subdomains such as intrinsic motivation may not always be strongly correlated with negative 
symptoms; this limited overlap may be particularly important when choosing measures for 
validation and treatment studies focused on these domains. Taken together, although 
additional research and discussion are needed to further develop consensus around gold 
standard motivation and negative symptom measures, our results offer preliminary 
suggestions for the most promising measures in these domains for motivation research.
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Fig. 1. 
PRISMA study retrieval flow diagram.
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Fig. 2. 
Forest plot of studies in the meta-analysis between motivation and clinician-rated negative 
symptom measures (k = 46) (Arbour-Nicitopoulos et al., 2014; Breitborde et al., 2014; Choi 
et al., 2012; Choi et al., 2016; DeRosse et al., 2014; Dowd et al., 2016; Duncan et al., 2016; 
Engel and Lincoln, 2016; Evensen et al., 2012; Fervaha et al., 2013b; Fervaha et al., 2014a; 
Fisher et al., 2017; Fiszdon et al., 2016; Fiszdon et al., 2017; Gard et al., 2014; Huang et al., 
2016; Jang et al., 2016a; Jang et al., 2016b; Kako et al., 2014; Keefe et al., 2012; Kiang et 
al., 2003; Kim et al., 2016; Lincoln et al., 2016; Liraud et al., 2004; Llerena et al., 2013; 
Minyaycheva et al., 2017; Nakaya et al., 2002; Papsuev et al., 2015; Reddy et al., 2015a; 
Schlier et al., 2015; Takeda et al., 2017; Tas et al., 2012; Vinogradov et al., 2013; Wang et 
al., 2015; Yon and Loas, 2000).
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Table 1
Overall characteristics across independent samples (k = 47)
Sample Characteristics Mean (SD) K
Age 38.4 (6.3) 47
Percent Female 39.0 (10.2) 47
Percent Diagnosisa 42
 Schizophrenia 83.9 (17.1) -
 Schizoaffective 13.2 (14.5) -
 Other Psychosis 2.8 (8.8) -
Length of illness 14.5 (6.4) 23
Chlorpromazine equivalent doses 513.3 (323.3) 20
Sample Characteristics Mean (SD) K
Data source (k, %) 47
 Published Articleb 44 (93.6) -
 Conference Abstract 3 (6.4) -
Median Year (range) 2015 (2000-2018) 47
Mean Sample size (range) 61.9 (12-482) 47
Study Location (k, %) 47
 Asia 11 (23.4) -
 Europe 9 (19.1) -
 North America 27 (57.4) -
aAll included samples had schizophrenia-spectrum disorder diagnoses.
b
Includes studies that were published as both a conference abstract and article.
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